ART150

ART150 is an antibody under development for the treatment of lung cancer and melanoma.

ART150 targets gangliosides (complex molecules made of carbohydrate and lipid that are present in the membranes of cells) and is currently in pre-clinical trials.

In a mouse model of human lung cancer, ART150 was able to completely inhibit tumour development, even after the completion of treatment.

The market for lung cancer therapies is about US$3 billion annually and that for melanoma therapies is about US$1 billion. Arana expects to complete preclinical development of ART150 in 2009.